Compare GameStop Corp. (GME) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs BIO-TECHNE Corp — how do they compare? GameStop Corp. trades at $22.28 (market cap $9.99B), while BIO-TECHNE Corp trades at $71.64 (market cap $11.14B). The key difference: GameStop Corp. and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | TECH | |
|---|---|---|
Market Cap | $9.99B | $11.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $71.48 |
52-Week Low | $19.94 | $43.31 |
Enterprise Value | $5.96B | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.43, up 1.82% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue for 2025 was $3.82 billion, with net income of $131.3 million, marking a significant turnaround from prior losses. Recent news highlights a partnership with Uber Eats and a proposed eBay acquisition as strategic growth catalysts.
The outlook is mixed; fundamentals show improving profitability and a robust balance sheet with $4.77 billion cash, but revenue declines and competitive pressures from digital game distribution pose risks. Analyst sentiment is cautious with only 16.7% buy ratings. Key opportunities include EBITDA guidance exceeding $600 million for 2026, while execution risks around the eBay bid and industry shifts remain headwinds.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
